Ro­mesh Sub­ra­man­ian births a new biotech with $50M and a plan to steer to­ward the clin­ic with drugs for rare mus­cle dis­eases

The At­las Ven­ture crew has nev­er liked be­ing splashy with mon­ey when it comes to star­tups. They like to get a good, lean team to­geth­er with some seed mon­ey, find an ex­pe­ri­enced helms­man on the bench, gath­er a string of ex­perts to lend ad­vice and of­fer enough cash in the A round — usu­al­ly with syn­di­cate part­ners — to see if they’re re­al­ly on­to some­thing with their lead drug. 

Maybe, the At­las team could even score a pre­clin­i­cal deal, like the one they did with Delinia. Be­cause they are al­ways on the look­out for a great X fac­tor re­turn for an in­vest­ment. The high­er the bet­ter. 10X will get a rous­ing cheer go­ing in this group. A fast 10X-plus works even bet­ter. And if it looks like too long a path to piv­otal da­ta, they’ve been known to bow out as well.

So along those lines, it’s not too sur­pris­ing to see the start­up mod­el Ro­mesh Sub­ra­man­ian is rolling in­to the biotech lane to­day.

Ja­son Rhodes

At­las, For­bion and MPM got to­geth­er to pro­vide the $50 mil­lion launch round, which will al­low the CEO to build up the crew as they build on the pre­clin­i­cal work they’ve been at for the past year or so — cour­tesy of At­las Ven­ture’s in­cu­ba­tion funds.

At­las’ Ja­son Rhodes will be play­ing a key role as ex­ec­u­tive chair­man, help­ing steer a com­pa­ny he co-found­ed.

The biotech is called Dyne Ther­a­peu­tics and they’ve been work­ing on us­ing oligonu­cleotides to de­grade RNA re­spon­si­ble for dis­ease — with a spe­cial fo­cus on mus­cle ail­ments.

Dyne has been de­vel­op­ing its own in-house con­ju­gate tech­nol­o­gy so they can take this ap­proach and care­ful­ly tar­get it to mus­cles. Ze­ro in close enough and you can amp up your dosage and avoid off-tar­get is­sues. 

Their first dis­ease is my­oton­ic dy­s­tro­phy type 1 — or DM1 — a rare, in­her­it­ed ail­ment that caus­es mus­cle weak­ness. The plan is to build a pipeline of ther­a­pies that can kick down gene ex­pres­sion for rare, mono­genic neu­ro­mus­cu­lar dis­eases, start­ing with skele­tal, car­diac and smooth mus­cle. And they want to stay fo­cused on break­through ther­a­pies.

“Fifty mil­lion takes us to the clin­ic,” says Sub­ra­man­ian. He’s not shar­ing any time­lines with me — not un­usu­al in a start­up’s ear­ly days. But with these back­ers, clear, track­able progress is baked in­to every­thing they do.

This is all fa­mil­iar ter­ri­to­ry for Sub­ra­man­ian, a well-known fig­ure in biotech, who did a stint as a se­nior sci­en­tist at Pfiz­er with Art Krieg be­fore mov­ing on to co-found RaNA and then set up trans­la­tion­al re­search groups for rare dis­eases at Alex­ion — up un­til Lud­wig Hantson’s big purge in the fall of 2017.

With­in months, he was build­ing the new com­pa­ny at At­las. These days, you see one door close, you po­ten­tial­ly get to have your pick of doors. 


Left to right: Sud­hir Agraw­al, Charles Thorn­ton, Louis Kunkel, Nan­cy An­drews.

Here’s their im­pres­sive list of sci­en­tif­ic ad­vis­ers help­ing Dyne stay on track:

— Nan­cy An­drews, for­mer dean of the School of Med­i­cine at Duke Uni­ver­si­ty and No­var­tis board mem­ber.

— Louis Kunkel, mem­ber of the Di­vi­sion of Ge­net­ics and Ge­nomics at Boston Chil­dren’s Hos­pi­tal and pro­fes­sor of pe­di­atrics and ge­net­ics at Har­vard Med­ical School.

— Charles Thorn­ton, Saun­ders Dis­tin­guished Pro­fes­sor of Neu­ro­mus­cu­lar Re­search at the Uni­ver­si­ty of Rochester.

— Sud­hir Agraw­al, vis­it­ing pro­fes­sor in the De­part­ment of Med­i­cine at The Uni­ver­si­ty of Mass­a­chu­setts Med­ical School and founder of Idera Phar­ma­ceu­ti­cals.

M&A: a crit­i­cal dri­ver for sus­tain­able top-line growth in health­care

2021 saw a record $600B in healthcare M&A activity. In 2022, there is an anticipated slowdown in activity, however, M&A prospects remain strong in the medium to long-term. What are future growth drivers for the healthcare sector? Where might we see innovations that drive M&A? RBC’s Andrew Callaway, Global Head, Healthcare Investment Banking discusses with Vito Sperduto, Global Co-Head, M&A.

15 LGBTQ lead­ers in bio­phar­ma; Paul Stof­fels’ Gala­pa­gos re­vamp; As­traZeneca catch­es up in AT­TR; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

A return to in-person conferences also marks a return to on-the-ground reporting. My colleagues Beth Synder Bulik and Nicole DeFeudis were on-site at Cannes Lions, bringing live coverage of pharma’s presence at the ad festival — accompanied by photos from Clara Bui, our virtual producer, that bring you right to the scene. You can find a recap (and links to all the stories) below.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Abortion-rights protesters regroup and protest following Supreme Court's decision to overturn Roe v. Wade. (AP Photo/Gemunu Amarasinghe)

Fol­low­ing SCO­TUS de­ci­sion to over­turn abor­tion pro­tec­tions, AG Gar­land says states can't ban the abor­tion pill

Following the Supreme Court’s historic decision on Friday to overturn Americans’ constitutional right to an abortion after almost 50 years, Attorney General Merrick Garland sought to somewhat reassure women that states will not be able to ban the prescription drug sometimes used for abortions.

Following the decision, the New England Journal of Medicine also published an editorial strongly condemning the reversal, saying it “serves American families poorly, putting their health, safety, finances, and futures at risk.”

AstraZeneca's new Evusheld direct to consumer campaign aims to reach more immunocompromised patients.

As­traZeneca de­buts first con­sumer cam­paign for its Covid-19 pro­phy­lac­tic Evusheld — and a first for EUA drugs

AstraZeneca’s first consumer ad for Evusheld is also a first for drugs that have been granted emergency use authorizations during the pandemic.

The first DTC ad for a medicine under emergency approval, the Evusheld campaign launching this week aims to raise awareness among immunocompromised patients — and spur more use.

Evusheld nabbed emergency authorization in December, however, despite millions of immunocompromised people looking for a solution and now more widespread availability of the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Yong Dai, Frontera Therapeutics CEO

Scoop: Lit­tle-known Or­biMed-backed biotech clos­es $160M round to start gene ther­a­py tri­al

Frontera Therapeutics, a China and US biotech, has closed a $160 million Series B and received regulatory clearance to test its first gene therapy stateside, Endpoints News has learned.

Led by the largest shareholder, OrbiMed, the biotech has secured $195 million total since its September 2019 founding, according to an email reviewed by Endpoints. The lead AAV gene therapy program is for an undisclosed rare eye disease, according to the source.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

DEM BioPharma CEO David Donabedian (L) and executive chair Jan Skvarka

Long­wood sets an­oth­er 'don't eat me' biotech in­to gear with help of for­mer Tril­li­um CEO Jan Skvar­ka

Jonathan Weissman and team are out with a cancer-fighting biotech riding the appetite for those so-called “don’t eat me” and “eat me” signals.

The scientific co-founder — alongside fellow Whitehead Institute colleague Kipp Weiskopf and Stanford biologist Michael Bassik — has launched DEM BioPharma with incubator Longwood Fund and a crop of other investors.

In all, the nascent, 10-employee biotech has $70 million to bankroll hematology- and solid tumor-based programs, including a lead asset that could enter human trials in two to three years, CEO David Donabedian told Endpoints News.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Spanish Prime Minister Pédro Sanchez and European Commission President Ursula von der Leyen (AP Photo/Geert Vanden Wijngaert)

EU to launch vac­cine de­vel­op­ment and man­u­fac­tur­ing part­ner­ship with Latin Amer­i­can and Caribbean coun­tries

While European companies, including BioNTech, are focused on increasing vaccine access to African countries by setting up vaccine manufacturing facilities, the European Union is looking westward to Latin America and the Caribbean.

Speaking at a press conference with Spanish Prime Minister Pédro Sanchez, EU Commission president Ursula von der Leyen said that the EU is launching a new initiative for vaccines and medicines manufacturing in Latin America, to get drugs to Latin America and the Caribbean faster.

GSK says its drug for chron­ic hep B could ‘lead to a func­tion­al cure’ — but will it be alone or in com­bi­na­tion?

GSK, newly branded and soon-to-be demerged, shared interim results from its Phase II trial on its chronic hepatitis B treatment, one that it says has the “potential to lead to a functional cure.”

At a presentation at the EASL International Liver Congress, GSK shared that in around 450 patients who received its hep B drug bepirovirsen for 24 weeks, just under 30% had hepatitis B surface antigen and viral DNA levels that were too low to detect.

De­spite a slow start to the year for deals, PwC pre­dicts a flur­ry of ac­tiv­i­ty com­ing up

Despite whispers of a busy year for M&A, deal activity in the pharma space is actually down 30% on a semi-annualized basis, according to PwC’s latest report on deal activity. But don’t rule out larger deals in the second half of the year, the consultants said.

PwC pharmaceutical and life sciences consulting solutions leader Glenn Hunzinger expects to see Big Pharma companies picking up earlier stage companies to try and fill pipeline gaps ahead of a slew of big patent cliffs. Though a bear market continues to maul the biotech sector, Hunzinger said recent deals indicate that pharma companies are still paying above current trading prices.